Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/spandidos-publications/immunotherapy-in-malignant-peritoneal-mesothelioma-review-4kK6h89XSf
References
References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.
- Publisher
- Spandidos Publications
- Copyright
- Copyright \xC2\xA9 2023 Spandidos Publications
- ISSN
- 2049-9450
Abstract
Over the last decade, there has been a movement in cancer treatment away from cytotoxic therapies toward strategies that enhance the immune system against cancer. Immune checkpoint inhibitors (ICIs) have been incorporated into the treatment regimens for patients with various solid tumors. Mesothelioma trials revealed encouraging efficacy; however, patients with peritoneal mesothelioma are usually excluded, slowing the progress of improving the treatment of this aggressive cancer and compelling oncologist to rely on retrospective studies despite their flaws and limitations. Currently, there is no consensus on the role of ICIs in the treatment of malignant peritoneal mesothelioma (MPeM). The present review discusses data from clinical studies that examined immunotherapy in MPeM and evaluates what is known about the relevance of the tumor microenvironment and clinically validated biomarkers for ICIs efficacy. Furthermore, a proposed strategy for utilizing immunotherapy in treating MPeM is discussed.
Journal
Molecular and Clinical Oncology – Spandidos Publications
Published: Apr 19, 2023